info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

India Thalassemia Market Research Report: Information by Type (Alpha-thalassemia and Beta-thalassemia) and by Treatment & Diagnosis (Treatment [Blood Transfusions, Drugs, Folic Acid Supplements] and Diagnosis [Instruments and Reagents) - Forecast till 2032


ID: MRFR/HC/20454-CR | 208 Pages | Author: Rahul Gotadki| May 2024

India Thalassemia Market Overview


India thalassemia market size was valued at USD 0.20 billion in 2022. The India thalassemia market industry is projected to grow from USD 0.21 billion in 2023 to USD 0.38 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.03% during the forecast period (2023 - 2032).


Growing government initiatives and support to raise awareness for thalassemia and increased prevalence of thalassemia in India are fueling the growth of the India thalassemia market.


India Thalassemia Market Overview


 Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


India Thalassemia Market Trends



  • Growing government initiatives and support to raise awareness for thalassemia


In recent years, the Indian government has taken significant steps towards raising awareness for thalassemia, a genetic blood disorder that affects a large number of people in the country. Government initiatives have played a crucial role in educating the public about thalassemia and its prevention methods. The Ministry of Health and Family Welfare has been actively involved in implementing various programs and campaigns to increase knowledge and understanding of this condition. For instance, in May 2023, Ministry of Health and Family Welfare (India) reported that Dr Bharati Pravin Pawar launched Phase-III of Thalassemia Bal Sewa Yojana. Furthermore, it also stated that combating blood disorders like Thalassemia requires a multi-pronged approach: ramping up screening efforts, bolstering awareness and counseling programs, and significantly expanding access to treatment facilities. These initiatives include organizing awareness camps, conducting medical screenings, and providing essential information about the disease to communities.


Moreover, the increased prevalence of thalassemia has indeed led to a higher demand for iron chelation therapy and folic acid supplements. Iron chelation therapy is essential in thalassemia patients to remove excess iron from the body and prevent complications such as organ damage, particularly in the heart and liver. The demand for iron chelators like deferasirox, deferiprone, and deferoxamine has increased with the rising prevalence of thalassemia cases. For instance, in August 2020, according to the Ministry of Health and Family Welfare in India, the country has the highest prevalence of thalassemia globally, with approximately 150,000 individuals affected, and an estimated 10,000 to 15,000 children born with the condition annually. Furthermore, supplementing with folic acid helps to support red blood cell production and can alleviate some of the symptoms of anemia associated with thalassemia.


Thus, the increasing government initiatives are creating huge awareness of thalassemia among Indian population and rising incidences of thalassemia in India are burgeoning the growth of India thalassemia.


India Thalassemia Market Segment Insights


India Thalassemia Type Insights


Based on type, the India thalassemia market is segmented into alpha-thalassemia and beta-thalassemia. Beta-thalassemia held the largest market share in 2022 and is anticipated to register the highest CAGR from 2022 to 2032. This is due to the factors such as rising prevalence of beta-thalassemia major (About 10,000 -15,000 babies with thalassemia major are born every year), growing emphasis on newborn screening programs for early identification and intervention, and increasing collaborations between pharmaceutical companies and research institutions.


India Thalassemia Treatment & Diagnosis Insights


Based on treatment & diagnosis, the India thalassemia market has been segmented into treatment and diagnosis. The treatment segment further divided into blood transfusions, drugs, and folic acid supplements immunoassay and diagnosis is bifurcated into instruments and reagents. Treatment held the largest market share in 2022 and diagnosis is anticipated to register the highest CAGR from 2022 to 2032. This growth is reflected due to some major factors such as rising prevalence of transfusion-dependent thalassemia patients, technological advancements in hemoglobinopathy testing, and advancements in genetic testing.


FIGURE 2: INDIA THALASSEMIA MARKET, BY TREATMENT & DIAGNOSIS, 2022 & 2032 (USD BILLION)


INDIA THALASSEMIA MARKET, BY TREATMENT & DIAGNOSIS, 2022 & 2032


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


India Thalassemia Key Market Players & Competitive Insights


The India thalassemia market is distinguished by the presence of numerous local players catering to thalassemia products that are evolving at a rapid pace. Furthermore, the rising prevalence of type 2 diabetes, increased prevalence of thalassemia, and sickle cell disease coupled with growing awareness among Indians is further driving the growth of India thalassemia market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products, services and signing contracts and agreements to broaden their reach and reduce operational costs.


Furthermore, Agios Pharmaceuticals Inc. (US) discovers and creates novel medications to treat rare genetic metabolic disorders and cancer. AG-946, a novel PKR activator for the treatment of sickle cell disease and hemolytic anemias, is one of its pipeline products. The drug candidate mitapivat is also part of the company's pipeline; it is intended to treat adult sickle cell disease, adult thalassemia, adult pyruvate kinase (PK) deficiency, adult thalassemia, and pediatric sickle cell disease. Adults with PK deficiency can treat their hemolytic anemia with tablets from Agios under the Pyrukynd brand. The business provides the myAgios patient support services program, which consists of financial aid, prescription fulfillment, access support, illness education, and connections to the community. The company's strategic collaborations and financial strength position it well for continued growth and success in the biopharmaceutical industry. Furthermore, the company distributes its products through online channel across the world including India. Additionally, the company the U.S. Food and Drug Administration (FDA) has approved PYRUKYND (mitapivat) for the treatment of adults with pyruvate kinase (PK) deficiency, a rare, lifelong hemolytic anemia that is crippling. The product is available in India.


Key Companies in the India Thalassemia Market includes.



  • Novartis AG (Switzerland)

  • Cipla, Inc. (India)

  • Sun Pharmaceutical Industries Ltd. (India)

  • Bristol-Myers Squibb (US)

  • Agios Pharmaceuticals, Inc. (US)

  • Centurion Remedies Private Limited. (India)

  • Healing Pharma India Pvt. Ltd. (India)

  • Rewine Pharmaceuticals (India)

  • Cadila Pharmaceuticals (India)

  • Trexgen Pharmaceuticals Pvt Ltd. (India)


India Thalassemia Market Industry Developments


February 2022: The U.S. Food and Drug Administration (FDA) has approved PYRUKYND (mitapivat) for the treatment of adults with pyruvate kinase (PK) deficiency, a rare, lifelong hemolytic anemia that is crippling. The product is available in India.


India Thalassemia Market Segmentation


India Thalassemia Type Outlook



  • Alpha-thalassemia

  • Beta-thalassemia


India Thalassemia Treatment & Diagnosis Outlook



  • Treatment

    • Blood Transfusions

    • Drugs

    • Folic Acid Supplements



  • Diagnosis

    • Instruments

    • Reagents



Report Attribute/Metric Details
Market Size 2022 USD 0.20 billion
Market Size 2023 USD 0.21 billion
Market Size 2032 USD 0.38 billion
Compound Annual Growth Rate (CAGR) 5.03% (2023-2032)
Base Year 2022
Forecast Period 2023-2032
Historical Data 2019 to 2021
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Type, and Treatment & Diagnosis
Key Companies Profiled Novartis AG (Switzerland), Cipla, Inc. (India), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb (US), Agios Pharmaceuticals, Inc. (US), Centurion Remedies Private Limited. (India), Healing Pharma India Pvt. Ltd. (India), Rewine Pharmaceuticals (India), Cadila Pharmaceuticals (India), and Trexgen Pharmaceuticals Pvt Ltd. (India)
Key Market Opportunities ·       Launch of services with advancements in prenatal and newborn screening technologies
Key Market Drivers ·       Growing government initiatives and support to raise awareness for thalassemia ·       Increased prevalence of thalassemia in India


Frequently Asked Questions (FAQ) :

The India thalassemia market is anticipated to reach 0.38 billion by 2032 at a CAGR of 5.03% during the forecast period of 2023-2032.

The India thalassemia market is expected to grow at an 5.03% CAGR during the forecast period from 2023 to 2032.

The key players include Novartis AG (Switzerland), Cipla, Inc. (India), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb (US), Agios Pharmaceuticals, Inc. (US), Centurion Remedies Private Limited. (India), Healing Pharma India Pvt. Ltd. (India), Rewine Pharmaceuticals (India), Cadila Pharmaceuticals (India), and Trexgen Pharmaceuticals Pvt Ltd. (India).

The beta-thalassemia of type segment led the India thalassemia market in 2022.

Treatment segment had the largest market in 2022 with a market share of around 64.00%.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.